Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Investment analysts at StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a report issued on Friday. The brokerage set a “sell” rating on the ...

Q3 2025 Earnings Call Transcript February 13, 2025 Operator: And good day. Thank you for standing by. Welcome to VistaGen ...

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) have received an average recommendation of “Buy” from ...

New research from The Lancet highlights persistent symptoms after the flu, similar to 'long Covid.' Veterans studied faced ...

The EPIC-B trial demonstrates the efficacy of cemiplimab monotherapy as a treatment for locally advanced or metastatic penile cancer (la/mPC). The trial met its primary endpoint, with a clinical ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...